\
&
Contact us
\
&
Contact us
Published on | 4 months ago
ProgrammesThe Collaborative Doctoral Partnership programme (CDP) is an initiative of the Commission's Joint Research Centre (JRC) to establish strategic collaborations with Partner Institutions, including higher education institutions and research organisations. The programme facilitates dual PhD projects, where Partner Institutions collaborate with the JRC to jointly design, host, and supervise doctoral research projects.
The 2026 Call for Expressions of Interest invites Partner Institutions to participate in the Collaborative Doctoral Partnership programme encompasses eight Collaboration Themes:
The JRC is looking to establish new CDP partnerships around each Collaboration Theme, with each theme resulting in up to four collaborative PhD projects.
More information, including on who can apply, selection criteria and the application form can be found here. The application deadline is 25 September 2026, 23.59 (CET).
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
